CVC  Lilly Ventures

http://www.lillyventures.com





     Office Locations:

115 W. Washington St, South Tower, Suite 1680
Indianapolis, IN 46204
Phone: 317-429-0140
Fax: 317-759-2819

 

Stages:

  • Early
  • Expansion
  • Growth


 

Industries:

  • Information Technology
  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. The fund's primary goal is to facilitate the success of companies in Lilly's areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest: Biotechnology, targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline; Healthcare IT, targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model; and Medical Technology, targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics. The fund also has a sister fund, Lilly Asian Ventures, which was established in 2007, and has a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Armen Shanafelt General Partner
    Lisa Belas Office Manager
    S. Edward Torres Co-Founder and Managing Director
    Steve Hall General Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      06/05/2018


      Nimbus Therapeutics


      MA


      $65,000,000


      Venture


      10/30/2017


      Kymera Therapeutics


      MA


      $30,000,000


      Series A


     

    Portfolio companies include:


      Aeglea Biotherapeutics
        web link


      Aileron Therapeutics
        web link


      Avid Radiopharmaceuticals
        web link


      Cavion
        web link


      Cerulean Pharma
        web link


      CGI Pharmaceuticals
        web link


      Coherus Biosciences
        web link


      Cylene Pharmaceuticals
        web link


      Forma Therapeutics
        web link


      GlobeImmune
        web link


      HemaQuest
        web link


      Hydra Biosciences
        web link


      InCube Ventures
        web link


      InnoCentive
        web link


      Innocrin Pharmaceuticals
        web link


      Intradigm
        web link


      Kymera Therapeutics
        web link


      Lysosomal Therapeutics
        web link


      Nimbus Discovery
        web link


      Nimbus Therapeutics
        web link


      Numerate
        web link


      Protagonist Therapeutics
        web link


      Receptos
        web link


      Serenex
        web link


      Surface Oncology
        web link


      Sutro Biopharma
        web link


      Symic Biomedical
        web link


      Viamet Pharmaceuticals
        web link


     

    Recent News:


      There is no recent news for Lilly Ventures.